Scott Strum, Seth Climans, Victoria Purcell, Morgan Black, Eric Winquist, Scott Ernst
{"title":"塞米普利单抗治疗晚期皮肤鳞状细胞癌的真实世界经验","authors":"Scott Strum, Seth Climans, Victoria Purcell, Morgan Black, Eric Winquist, Scott Ernst","doi":"10.1177/12034754241265696","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer in Canada. However, few real-world reports exist on the treatment of refractory locally advanced (LA) and metastatic cSCC with cemiplimab to date.</p><p><strong>Objectives: </strong>The objective of this study was to characterize the demographic and clinical outcomes of advanced cSCC patients on cemiplimab in a real-world setting.</p><p><strong>Methods: </strong>Retrospective analysis of adult patients with refractory LA and metastatic cSCC treated with cemiplimab at the London Regional Cancer Program in Canada. Patient demographics and treatment characteristics were reported, as well as Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>Forty patients were included in this study. Sixteen (40%) had LA disease and 24 (60%) had metastatic disease. Median treatment duration was 3.5 months (range: 0.6-29.4 months). Kaplan-Meier analyses of the entire study population revealed that the median OS was not reached [NR; 95% confidence interval (CI) 9.1 months-NR], but median PFS was 11.5 months (95% CI 7.0 months-NR). A total of 25% of patients experienced at least one adverse event from cemiplimab. Reasons for treatment discontinuation were death from any cause (25%), disease progression (15%), cemiplimab adverse events (5%), and other causes (15%).</p><p><strong>Discussion: </strong>The 12 month estimates of OS and PFS were lower than pivotal phase I and II clinical trials. However, toxicity was tolerable. Cemiplimab remains a safe and effective therapy in patients with refractory LA and metastatic cSCC disease.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma.\",\"authors\":\"Scott Strum, Seth Climans, Victoria Purcell, Morgan Black, Eric Winquist, Scott Ernst\",\"doi\":\"10.1177/12034754241265696\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer in Canada. However, few real-world reports exist on the treatment of refractory locally advanced (LA) and metastatic cSCC with cemiplimab to date.</p><p><strong>Objectives: </strong>The objective of this study was to characterize the demographic and clinical outcomes of advanced cSCC patients on cemiplimab in a real-world setting.</p><p><strong>Methods: </strong>Retrospective analysis of adult patients with refractory LA and metastatic cSCC treated with cemiplimab at the London Regional Cancer Program in Canada. Patient demographics and treatment characteristics were reported, as well as Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>Forty patients were included in this study. Sixteen (40%) had LA disease and 24 (60%) had metastatic disease. Median treatment duration was 3.5 months (range: 0.6-29.4 months). Kaplan-Meier analyses of the entire study population revealed that the median OS was not reached [NR; 95% confidence interval (CI) 9.1 months-NR], but median PFS was 11.5 months (95% CI 7.0 months-NR). A total of 25% of patients experienced at least one adverse event from cemiplimab. Reasons for treatment discontinuation were death from any cause (25%), disease progression (15%), cemiplimab adverse events (5%), and other causes (15%).</p><p><strong>Discussion: </strong>The 12 month estimates of OS and PFS were lower than pivotal phase I and II clinical trials. However, toxicity was tolerable. Cemiplimab remains a safe and effective therapy in patients with refractory LA and metastatic cSCC disease.</p>\",\"PeriodicalId\":15403,\"journal\":{\"name\":\"Journal of Cutaneous Medicine and Surgery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cutaneous Medicine and Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/12034754241265696\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Medicine and Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/12034754241265696","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:皮肤鳞状细胞癌(cSCC)是加拿大第二大最常见的非黑色素瘤皮肤癌。然而,迄今为止,关于用塞米普利姆单抗治疗难治性局部晚期(LA)和转移性 cSCC 的真实报道很少:本研究旨在描述在真实世界环境中使用塞米普利单抗的晚期 cSCC 患者的人口统计学特征和临床结果:方法:回顾性分析加拿大伦敦地区癌症项目使用塞米普利单抗治疗的难治性LA和转移性cSCC成年患者。报告了患者的人口统计学特征和治疗特征,以及无进展生存期(PFS)和总生存期(OS)的卡普兰-梅耶估计值:本研究共纳入 40 名患者。16人(40%)患有LA疾病,24人(60%)患有转移性疾病。中位治疗时间为 3.5 个月(范围:0.6-29.4 个月)。对整个研究人群进行的卡普兰-梅耶尔分析显示,中位OS未达到[NR;95%置信区间(CI)9.1个月-NR],但中位PFS为11.5个月(95% CI 7.0个月-NR)。共有25%的患者因塞米普利单抗至少出现过一次不良反应。终止治疗的原因包括任何原因导致的死亡(25%)、疾病进展(15%)、cemiplimab不良事件(5%)和其他原因(15%):讨论:12个月的OS和PFS估计值低于关键的I期和II期临床试验。然而,毒性是可以耐受的。对于难治性 LA 和转移性 cSCC 患者来说,塞米普利单抗仍然是一种安全有效的疗法。
Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma.
Background: Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer in Canada. However, few real-world reports exist on the treatment of refractory locally advanced (LA) and metastatic cSCC with cemiplimab to date.
Objectives: The objective of this study was to characterize the demographic and clinical outcomes of advanced cSCC patients on cemiplimab in a real-world setting.
Methods: Retrospective analysis of adult patients with refractory LA and metastatic cSCC treated with cemiplimab at the London Regional Cancer Program in Canada. Patient demographics and treatment characteristics were reported, as well as Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS).
Results: Forty patients were included in this study. Sixteen (40%) had LA disease and 24 (60%) had metastatic disease. Median treatment duration was 3.5 months (range: 0.6-29.4 months). Kaplan-Meier analyses of the entire study population revealed that the median OS was not reached [NR; 95% confidence interval (CI) 9.1 months-NR], but median PFS was 11.5 months (95% CI 7.0 months-NR). A total of 25% of patients experienced at least one adverse event from cemiplimab. Reasons for treatment discontinuation were death from any cause (25%), disease progression (15%), cemiplimab adverse events (5%), and other causes (15%).
Discussion: The 12 month estimates of OS and PFS were lower than pivotal phase I and II clinical trials. However, toxicity was tolerable. Cemiplimab remains a safe and effective therapy in patients with refractory LA and metastatic cSCC disease.
期刊介绍:
Journal of Cutaneous Medicine and Surgery (JCMS) aims to reflect the state of the art in cutaneous biology and dermatology by providing original scientific writings, as well as a complete critical review of the dermatology literature for clinicians, trainees, and academicians. JCMS endeavours to bring readers cutting edge dermatologic information in two distinct formats. Part of each issue features scholarly research and articles on issues of basic and applied science, insightful case reports, comprehensive continuing medical education, and in depth reviews, all of which provide theoretical framework for practitioners to make sound practical decisions. The evolving field of dermatology is highlighted through these articles. In addition, part of each issue is dedicated to making the most important developments in dermatology easily accessible to the clinician by presenting well-chosen, well-written, and highly organized information in a format that is interesting, clearly presented, and useful to patient care.